Dr. Mato is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-2000- Is this information wrong?
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2005 - 2008- University of Pennsylvania Health SystemResidency, Internal Medicine, 2002 - 2005
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2002
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2009 - 2025
NY State Medical License 2017 - 2025
NC State Medical License 2020 - 2022
OK State Medical License 2020 - 2021
ME State Medical License 2020 - 2021
PA State Medical License 2002 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax Start of enrollment: 2020 May 13
- The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2020 Dec 03
- A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Start of enrollment: 2020 Dec 22
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsKinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.Skye Montoya, Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C Thompson, Alexandra Chirino, Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Stephanie Yun...> ;Science. 2024 Feb 2
- Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.Ryan N Ptashkin, Mark D Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S Bowman, JinJuan Yao, Jacklyn Casanova, Yun-Te David Lin, Kseniya Petrova-Drus, Abhinita S Moh...> ;Nature Communications. 2023 Oct 28
- 18 citationsDetailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.John F Seymour, John C Byrd, Paolo Ghia, Arnon P Kater, Asher Chanan-Khan, Richard R Furman, Susan O'Brien, Jennifer R Brown, Talha Munir, Anthony Mato, Stephan Stilge...> ;Blood. 2023 Aug 24
- Join now to see all
Press Mentions
Nurix Therapeutics Presents Positive Clinical Results from Its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual MeetingDecember 12th, 2022- What’s Better for CLL: Sequential or Combination Therapy?October 4th, 2022
- Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate UpdateJuly 7th, 2022
- Join now to see all
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York
Cayuga Medical Center at IthacaIthaca, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
